Stwardnienie rozsiane – diagnostyka i leczenie Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
wrz 30, 2022
Słowa kluczowe:
stwardnienie rozsiane, farmakoterapia, przebieg kliniczny, nowe leczenie
##plugins.themes.bootstrap3.article.main##
Abstrakt
Wprowadzone niedawno do terapii stwardnienia rozsianego nowe leki mają znacznie większą skuteczność w zmniejszaniu częstości nawrotów i rozwoju niepełnosprawności. Z tego powodu konieczna wydaje się zmiana podejścia terapeutycznego i szybsze wprowadzenie nowych, wysoce skutecznych leków. W pracy zaprezentowano wyniki badań uzasadniające wprowadzanie terapii o wysokiej skuteczności jako leczenia pierwszego wyboru dla pacjentów z aktywną rzutowo-remisyjną postacią stwardnienia rozsianego.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Stępień, A. (2022). Stwardnienie rozsiane – diagnostyka i leczenie . Medycyna Faktów , 15(3(56), 278-282. https://doi.org/10.24292/01.MF.0322.1
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Guthrie E. Multiple sclerosis: a primer and update. Adv Studies Pharm. 2007; 4(11): 313-7.
2. Multiple Sclerosis International Federation. Atlas of MS 2020-Mapping multiple sclerosis around the world . [last accessed: January 2021].
3. Pugliatti M, Rosati G, Carton H et al. The epidemiology of multiple sclerosis in Europe. Eur J Neurol. 2006; 13: 700-22. http://doi.org/10.1111/j.1468-1331.2006.01342.x .
4. Kapica-Topczewska K, Brola W, Fudala M et al. Prevalence of multiple sclerosis in Poland. Mult Scler Relat Disord. 2018; 21: 51-5. http://doi.org/10.1016/j.msard.2018.02.016.
5. Potemkowski A. Epidemiology of multiple sclerosis in the region of Szczecin: prevalence and incidence 1993-1995. Neurol Neurochir Pol. 1999; 33: 575-85.
6. Cree BAC, Gourraud PA, Oksenberg JR. Longterm evolution of multiple sclerosis disability in the treatment era. Ann Neurol. 2016; 80(4): 499-510. http://doi.org/10.1002/ana.24747.
7. Thompson AJ, Banwell BL, Barkhof F et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018; 17(2): 162-73. http://doi.org/10.1016/ S1474-4422(17)30470-2.
8. Lorscheider J, Buzzard K, Jokubaitis V et al.; on behalf of the MSBase Study Group. Defining secondary progressive multiple sclerosis. Brain. 2016; 139(9): 2395-405. https://doi.org/10.1093/brain/aww173.
9. National MS Society. Types of MS . Last accessed: January 2021.
10. Langer-Gould A, Popat RA, Huang SM et al. Clinical and demographic predictors of long-term disability in patients with relapsing-remitting multiple sclerosis: a systematic review. Arch Neurol. 2006; 63: 1686-91.
11. Giovannoni G, Bermel R, Phillips T, et al. A brief history of NEDA. Mult Scler Relat Disord 2018; 20: 228-230.
12. Cree C, Gourraud PA, Oksenberg JR et al. Longterm evolution of multiple sclerosis disability in the treatment era. Ann Neurol. 2016; 80(4): 499-510. http://doi.org/10.1002/ana.24747.
13. Tremlett H, Devonshire V. Is late-onset multiple sclerosis associated with a worse outcome? Neurology. 2006; 67: 954-9.
14. Vukusic S, Confavreux C. Natural history of multiple sclerosis: risk factors and prognostic indicators. Curr Opin Neurol. 2007; 20: 269-74.
15. Confavreux C, Vukusic S, Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process Brain. 2003; 126: 770-82.
16. Stephen H. Mobility device use in the United States. Disability statistics report 14 MF01/PC03 Plus Postage [online]. Available at: dsc.ucsf.edu.
17. NFZ. Programy profilaktyczne .
18. Brown JWL, Coles A, Horakowa D. Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis. JAMA. 2019; 321(2): 175-87. https://doi.org/10.1001/jama.2018.20588.
19. Spelman T, Magyari M, Piehl F et al. Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple Sclerosis: Data From 2 Different National Strategies. JAMA Neurol. 2021; 78(10): 1197-204. https://doi.org/10.1001/jamaneurol.2021.2738.
20. He A, Merkel B, Brown JWL et al. Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study Lancet Neurology. 2020. https://doi.org/10.1016/S1474-4422 (20) 30067-3.
2. Multiple Sclerosis International Federation. Atlas of MS 2020-Mapping multiple sclerosis around the world . [last accessed: January 2021].
3. Pugliatti M, Rosati G, Carton H et al. The epidemiology of multiple sclerosis in Europe. Eur J Neurol. 2006; 13: 700-22. http://doi.org/10.1111/j.1468-1331.2006.01342.x .
4. Kapica-Topczewska K, Brola W, Fudala M et al. Prevalence of multiple sclerosis in Poland. Mult Scler Relat Disord. 2018; 21: 51-5. http://doi.org/10.1016/j.msard.2018.02.016.
5. Potemkowski A. Epidemiology of multiple sclerosis in the region of Szczecin: prevalence and incidence 1993-1995. Neurol Neurochir Pol. 1999; 33: 575-85.
6. Cree BAC, Gourraud PA, Oksenberg JR. Longterm evolution of multiple sclerosis disability in the treatment era. Ann Neurol. 2016; 80(4): 499-510. http://doi.org/10.1002/ana.24747.
7. Thompson AJ, Banwell BL, Barkhof F et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018; 17(2): 162-73. http://doi.org/10.1016/ S1474-4422(17)30470-2.
8. Lorscheider J, Buzzard K, Jokubaitis V et al.; on behalf of the MSBase Study Group. Defining secondary progressive multiple sclerosis. Brain. 2016; 139(9): 2395-405. https://doi.org/10.1093/brain/aww173.
9. National MS Society. Types of MS . Last accessed: January 2021.
10. Langer-Gould A, Popat RA, Huang SM et al. Clinical and demographic predictors of long-term disability in patients with relapsing-remitting multiple sclerosis: a systematic review. Arch Neurol. 2006; 63: 1686-91.
11. Giovannoni G, Bermel R, Phillips T, et al. A brief history of NEDA. Mult Scler Relat Disord 2018; 20: 228-230.
12. Cree C, Gourraud PA, Oksenberg JR et al. Longterm evolution of multiple sclerosis disability in the treatment era. Ann Neurol. 2016; 80(4): 499-510. http://doi.org/10.1002/ana.24747.
13. Tremlett H, Devonshire V. Is late-onset multiple sclerosis associated with a worse outcome? Neurology. 2006; 67: 954-9.
14. Vukusic S, Confavreux C. Natural history of multiple sclerosis: risk factors and prognostic indicators. Curr Opin Neurol. 2007; 20: 269-74.
15. Confavreux C, Vukusic S, Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process Brain. 2003; 126: 770-82.
16. Stephen H. Mobility device use in the United States. Disability statistics report 14 MF01/PC03 Plus Postage [online]. Available at: dsc.ucsf.edu.
17. NFZ. Programy profilaktyczne .
18. Brown JWL, Coles A, Horakowa D. Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis. JAMA. 2019; 321(2): 175-87. https://doi.org/10.1001/jama.2018.20588.
19. Spelman T, Magyari M, Piehl F et al. Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple Sclerosis: Data From 2 Different National Strategies. JAMA Neurol. 2021; 78(10): 1197-204. https://doi.org/10.1001/jamaneurol.2021.2738.
20. He A, Merkel B, Brown JWL et al. Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study Lancet Neurology. 2020. https://doi.org/10.1016/S1474-4422 (20) 30067-3.